First Generic Version of Xeloda Approved
To treat colorectal or breast cancers (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 16, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news
FDA approves first generic capecitabine to treat colorectal and breast cancers
The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 16, 2013 Category: American Health Source Type: news
Incyte reports results from Phase II proof-of-concept trial of ruxolitinib
Incyte has reported top-line results from a Phase II proof-of-concept trial of an oral JAK1 and JAK2 inhibitor, ruxolitinib, as combination therapy with capecitabine in patients with refractory metastatic pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - August 21, 2013 Category: Pharmaceuticals Source Type: news
A C-change in Adjuvant Pancreas Cancer?A C-change in Adjuvant Pancreas Cancer?
Dr. John Marshall reports on progress in treatment of metastatic pancreas cancer using traditional drugs, and questions current use of adjuvant capecitabine on the basis of a recent study from Japan. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Chemoradiation Therapy for the Treatment of Bone Metastases
The combination of the chemotherapy capecitabine with external beam radiation was found to be both safe and effective in treating pain from bone metastases in patients with advanced breast cancer. (Source: Cancer Network)
Source: Cancer Network - August 2, 2013 Category: Cancer & Oncology Source Type: news
Adjuvant Chemo Boosts Survival in Advanced Stomach CancerAdjuvant Chemo Boosts Survival in Advanced Stomach Cancer
Mature data from a phase 3 trial confirm that capecitabine plus oxaliplatin after gastrectomy yields a significant survival advantage over surgery alone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Study confirms adding chemotherapy to surgery improves survival in advanced gastric cancer
(European Society for Medical Oncology) At the meeting Prof Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea, presented 5-year follow-up from the phase III CLASSIC trial, which added combination chemotherapy to a standard surgical procedure called D2 gastrectomy. The chemotherapy regimen studied in the trial is called XELOX, which is a combination of the drugs capecitabine and oxaliplatin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 3, 2013 Category: Global & Universal Source Type: news
Greater Potential Benefit In Overall Survival For Eribulin Compared With Capecitabine For Metastatic Breast Cancer
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with metastatic breast cancer. This analysis was presented by Peter A. Kaufman, M.D., during the 2013 ASCO Annual Meeting... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 17, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Study finds greater potential benefit in overall survival for eribulin compared with capecitabine
(Dartmouth-Hitchcock Medical Center) Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with metastatic breast cancer. This analysis was presented by Peter A. Kaufman, M.D., during the 2013 ASCO Annual Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2013 Category: Global & Universal Source Type: news
Xeloda for Metastatic Breast Cancer
Xeloda or capecitabine is an oral chemotherapy drug that you take twice a day with water and on a full stomach. It is used to treat metastatic breast cancer, and can be taken alone or with Taxotere. Read more to learn about how Xeloda works, its side effects, and self-care tips. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 10, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Docetaxel-Cisplatin and Docetaxel-Capecitabine in TNBCDocetaxel-Cisplatin and Docetaxel-Capecitabine in TNBC
Should platinum be the gold-standard in triple-negative breast cancer treatment regimens? Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 3, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Vismodegib and Enzalutamide Recommended for EU ApprovalVismodegib and Enzalutamide Recommended for EU Approval
In addition, 2 generic cancer drugs have been recommended for approval in Europe: the oral agents capecitabine and imatinib. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Capecitabine shows promise in pancreatic cancer
(Source: HemOncToday.com)
Source: HemOncToday.com - April 17, 2013 Category: Cancer & Oncology Source Type: news
Horizon scanning: US FDA approves ado-trastuzumab emtansine or T-DM1 (KadcylaT) for HER2-positive metastatic breast cancer
Source: BioSpace
Area: News
The US FDA has approved the antibody-drug conjugate ado-trastuzumab emtansine or T-DM1 (KadcylaT) for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with trastuzumab (Herceptin®) and a taxane.
KadcylaT, which is composed of the cytotoxic agent DM1 conjugated to trastuzumab, is the first antibody-drug conjugate to be approved by the FDA for the treatment of metastatic breast cancer. The approval was based on the results of the EMILIA Phase III study (n=991), which compared KadcylaT alone to lapatinib in combination with capecit...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
Capecitabine Chemoradiotherapy Effective in Local Pancreatic Cancer
SAN FRANCISCO (IMNG) - Following induction chemotherapy with radiotherapy plus capecitabine seemed to be equally effective and less toxic compared with following with radiotherapy plus gemcitabine in a... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 16, 2013 Category: Cancer & Oncology Source Type: news
